A Review of Nasal Retinopathy of Prematurity Cases

Dong Cheol Lee; Kwang Soo Kim; Yu Cheol Kim

doi:10.3341/jkos.2011.52.12.1485

Journal List > J Korean Ophthalmol Soc > v.52(12) > 1008955

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Lee, Kim, and Kim: A Review of Nasal Retinopathy of Prematurity Cases

Original Article

J Korean Ophthalmol Soc 2011;52(12):1485-1489.

Published online: 7 September 2011

DOI: https://doi.org/10.3341/jkos.2011.52.12.1485

A Review of Nasal Retinopathy of Prematurity Cases

Dong Cheol Lee, MD, Kwang Soo Kim, MD, Yu Cheol Kim, MD

Department of Ophthalmology, Keimyung University College of Medicine, Daegu, Korea

Address reprint requests to Yu Cheol Kim, MD Department of Ophthalmology, Keimyung University Dongsan Medical Center #56 Dalseong-ro, Jung-gu, Daegu 700-712, Korea Tel: 82-53-250-8026, 7707, Fax: 82-53-250-7705, E-mail: eyedr@dsmc.or.kr

Received 26 January 20115 July 2011 Accepted 12 October 2011

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

The present study evaluated the developmental characteristics and causes of nasal retinopathy of prematurity (ROP).

Methods

A total of 111 eyes from 56 ROP-affected infants who had been treated with laser photocoagulation by retina specialists at the nasal site were examined. The gestational age at birth and diagnosis, location of the lesion, time, and number of laser photocoagulation therapies for nasal and temporal ROP were analyzed.

Results

Thirty-three cases (29.7%) were diagnosed with nasal ROP. The mean gestational age at birth was 28.43 weeks for nasal ROP, and 29.44 weeks for temporal ROP (p = 0.022). Additionally, the average gestational age of infants who received laser photocoagulation was 36.61 weeks for nasal ROP, and 39.71 weeks for temporal ROP (p = 0.001). The average number of ROP laser photocoagulation trials was 2936.03 for nasal ROP, and 1611.83 for temporal ROP (p = 0.0001). No case was observed with a wider avascular area in the nasal retina than in the temporal retina. Additionally, compared to the temporal ROP, the nasal ROP showed significant difference in progression rates, 33.3% in the nasal group and 8.97% in the temporal group (p = 0.001).

Conclusions

Nasal ROP was due to the ROP lesions developing earlier in the nasal than the temporal retina, although not due to any atypically wider nasal avascular area. In these cases, nasal ROP showed more disease progression compared to temporal ROP.

Keywords: Avascular area, Laser photocoagulation therapy, Lesion, Mean gestational age, Nasal retinopathy of pre-maturity

References

1. Terry TL. Retrolental fibroplasia in the premature infant: V. further studies on fibroplastic overgrowth of the persistent tunica vasculo-sa lentis. Trans Am Ophthalmol Soc. 1944; 42:383–96.

2. Hardy RJ, Palmer EA, Dobson V, et al. Risk analysis of prethres-hold retinopathy of prematurity. Arch Ophthalmol. 2003; 121:1697–701.

3. Watts P, Adams GG, Thomas RM, Bunce C. Intraventricular hae-morrhage and stage 3 retinopathy of prematurity. Br J Ophthalmol. 2000; 84:596–9.

4. Gibson DL, Sheps SB, Uh SH, et al. Retinopathy of pre-maturity-induced blindness: birth weight-specific survival and new epidemic. Pediatrics. 1990; 86:405–12.

5. Nissenkorn I, Yassur Y, Mashkowski D, et al. Myopia in premature babies with and without retinopathy of prematurity. Br J Ophthalmol. 1983; 67:170–3.

6. Hungerford J, Stewart A, Hope P. Ocular sequelae of preterm birth and their relation to ultrasound evidence of cerebral damage. Br J Ophthalmol. 1986; 70:463–8.

7. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for retinopathy of prematurity cooperative group. Arch Ophthalmol. 1988; 106:471–9.

8. Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome-structure and function. Cryotherapy for retinopathy of prematurity cooperative group. Arch Opthalmol. 1990; 108:1408–16.

9. McNamara JA, Tasman W, Brown GC, Federman JL. Laser photocoagulation for stage 3+ retinopathy of prematurity. Ophthalmology. 1991; 98:576–80.

10. Hunter DG, Repka MX. Diode laser photocoagulation for threshold retinopathy of prematurity. A randomized study. Ophthalmology. 1993; 100:238–44.

11. Trese MT. Scleral buckling for retinopathy of prematurity. Ophthalmology. 1994; 101:23–6.

12. Zilis JD, de Juan E, Machemer R. Advanced retinopathy of prematurity. The anatomic and visual results of vitreous surgery. Ophthalmology. 1990; 97:821–6.

13. Keith CG, Kitchen WH. Ocular morbidity in infants of very low birth weight. Br J Ophthalmol. 1983; 67:302–5.

14. Tasman W. Management of retinopathy of prematurity. Ophthalmology. 1985; 92:995–9.

15. Ben-Sira I, Nissenkorn I, Kremer I. Retinopathy of prematurity. Surv Ophthalmol. 1988; 33:1–16.

16. Noonan CP, Clark DI. Trends in the management of stage 3 retinopathy of prematurity. Br J Ophthalmol. 1996; 80:278–81.

17. Early treatment for retinopathy of prematurity cooperative group. Revised indications for the treatment of retinopathy of pre-maturity: results of the early treatment for retinopathy of pre-maturity randomized trial. Arch Ophthalmol. 2003; 121:1684–94.

18. Cogan DG. Development and senescence of the human retinal vasculature. Trans Ophthalmol Soc UK. 1963; 83:465–89.

19. Patz A. The role of oxygen in retrolental fibroplasia. Pediatrics. 1957; 19:504–24.

20. Donahue ML, Phelps DL, Watkins RH, et al. Retinal vascular endothelial growth factor (VEGF) mRNA expression is altered in relation to neovascularization in oxygen induced retinopathy. Curr Eye Res. 1996; 15:175–84.

21. Kretzer FL, Mehta RS, Johnson AT, et al. Vitamin E protects against retinopathy of prematurity through action on spindle cells. Nature. 1984; 309:793–5.

22. Flynn JT. Retinopathy of prematurity. Pediatr Clin North Am. 1987; 34:1487–516.

23. Michaelson IC. The mode of development of the vascular system of the retina with some observations on its significance of certain retinal diseases. Trans Ophthalmol Soc UK. 1948; 68:157–80.

24. Nissenkorn I, Kremer I, Cohen S, Ben-Sira I. Nasal versus temporal preretinal vasoproliferation in retinopathy of prematurity. Br J Ophthalmol. 1989; 73:747–9.

25. Capone A Jr, Diaz-Rohena R, Sternberg P Jr, et al. Diode-laser photocoagulation for zone I threshold retinopathy of prematurity. Am J Ophthalmol. 1993; 116:444–50.

26. Palmer EA, Flynn JT, Hardy RJ, et al. Incidence and early course of retinopathy of prematurity. The cryotherapy for retinopathy of pre-maturity cooperative group. Ophthalmology. 1991; 98:1628–40.

Table 1.

The characteristics of patients with ROP

Items	ROP		p-value
Items	Group I^∗	Group II^†	p-value
Eye (n [%])	33 (29.7)	78 (70.3)
Sex (M:F)	6 : 11	18 : 22
Body weight (mean ± SD, g)	1111.82 ± 219.62	1358.33 ± 359.19	0.0001

^∗ Group I = retinopathy of prematurity observed first at the nasal site when diagnosed

^† Group II = retinopathy of prematurity observed first at the temporal site when diagnosed.

ROP = retinopathy of prematurity.

Table 2.

The comparisons of mean PMA between nasal and temporal ROP at birth and screening test

Items	ROP		p-value
Items	Group I^∗	Group II^†	p-value
Mean PMA at birth (wk)	28.43 ± 1.95	29.44 ± 2.15	0.022
Mean PMA at screening test (wk)	35.50 ± 2.45	38.28 ± 2.05	0.001

Values are presented as mean ± SD.

^∗ Group I = retinopathy of prematurity observed first at the nasal site when diagnosed

^† Group II = retinopathy of prematurity observed first at the temporal site when diagnosed.

PMA = postmenstrual age; ROP = retinopathy of prematurity.

Table 3.

The comparisons of mean PMA and numbers of laser spots between nasal and temporal ROP at time of laser photocoagulation

Items	ROP		p-value
Items	Group I^∗	Group II^†	p-value
Mean PMA (wk)	36.61 ± 2.25	39.71 ± 2.32	0.001
Numbers of laser spot	2936.03 ± 1061.98	1611.83 ± 815.37	0.0001

Values are presented as mean ± SD.

^∗ Group I = retinopathy of prematurity observed first at the nasal site when diagnosed

^† Group II = retinopathy of prematurity observed first at the temporal site when diagnosed.

PMA = postmenstrual age; ROP = retinopathy of prematurity.

Table 4.

The rate of progression between nasal and temporal ROP after laser photocoagulation

Items	ROP		p-value
Items	Group I^∗	Group II^†	p-value
Progression rate	11/33 (33.3%)	7/78 (8.97%)	0.001

^∗ Group I = retinopathy of prematurity observed first at the nasal site when diagnosed

^† Group II = retinopathy of prematurity observed first at the temporal site when diagnosed.

ROP = retinopathy of prematurity.

TOOLS

Similar articles